4.7 Article

Associations of Early Systolic Blood Pressure Control and Outcome After Thrombolysis-Eligible Acute Ischemic Stroke: Results From the ENCHANTED Study

期刊

STROKE
卷 53, 期 3, 页码 779-787

出版社

LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1161/STROKEAHA.121.034580

关键词

blood pressure; hypertension; intracranial hemorrhage; ischemic stroke

资金

  1. National Health and Medical Research Council (NHMRC) of Australia [1020462, 1101113, 1149987]
  2. Stroke Association of the United Kingdom [TSA 2012/01, 2015/01]
  3. Ministry of Health
  4. National Council for Scientific and Technological Development of Brazil [CNPQ: 467322/2014-7, 402388/2013-5]
  5. Ministry for Health, Welfare and Family Affairs of the Republic of Korea [HI14C1985]
  6. National Institute for Health Research Clinical Research Network (NIHR CRN)
  7. National Heart Foundation of Australia postdoctoral fellowship
  8. New South Wales Health commission, Australia
  9. NHMRC
  10. Takeda

向作者/读者索取更多资源

Post hoc analysis of thrombolyzed acute ischemic stroke patients showed that reducing systolic blood pressure and decreasing systolic blood pressure variability were associated with better recovery outcomes, while the magnitude of systolic blood pressure reduction did not affect the outcomes. Higher systolic blood pressure and greater systolic blood pressure variability were associated with an increased risk of intracranial hemorrhage.
BACKGROUND AND PURPOSE: In thrombolysis-eligible patients with acute ischemic stroke, there is uncertainty over the most appropriate systolic blood pressure (SBP) lowering profile that provides an optimal balance of potential benefit (functional recovery) and harm (intracranial hemorrhage). We aimed to determine relationships of SBP parameters and outcomes in thrombolyzed acute ischemic stroke patients. METHODS: Post hoc analyzes of the ENCHANTED (Enhanced Control of Hypertension and Thrombolysis Stroke Study), a partial-factorial trial of thrombolysis-eligible and treated acute ischemic stroke patients with high SBP (150-180 mm Hg) assigned to low-dose (0.6 mg/kg) or standard-dose (0.9 mg/kg) alteplase and intensive (target SBP, 130-140 mm Hg) or guideline-recommended (target SBP <180 mm Hg) treatment. All patients were followed up for functional status and serious adverse events to 90 days. Logistic regression models were used to analyze 3 SBP summary measures postrandomization: attained (mean), variability (SD) in 1-24 hours, and magnitude of reduction in 1 hour. The primary outcome was a favorable shift on the modified Rankin Scale. The key safety outcome was any intracranial hemorrhage. RESULTS: Among 4511 included participants (mean age 67 years, 38% female, 65% Asian) lower attained SBP and smaller SBP variability were associated with favorable shift on the modified Rankin Scale (per 10 mm Hg increase: odds ratio, 0.76 [95% CI, 0.71-0.82]; P<0.001 and 0.86 [95% CI, 0.76-0.98]; P=0.025) respectively, but not for magnitude of SBP reduction (0.98, [0.93-1.04]; P=0.564). Odds of intracranial hemorrhage was associated with higher attained SBP and greater SBP variability (1.18 [1.06-1.31]; P=0.002 and 1.34 [1.11-1.62]; P=0.002) but not with magnitude of SBP reduction (1.05 [0.98-1.14]; P=0.184). CONCLUSIONS: Attaining early and consistent low levels in SBP <140 mm Hg, even as low as 110 to 120 mm Hg, over 24 hours is associated with better outcomes in thrombolyzed acute ischemic stroke patients. Registration: URL: ; Unique identifier: NCT01422616.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据